Your browser is no longer supported. Please, upgrade your browser.
Settings
PDLI PDL BioPharma, Inc. daily Stock Chart
PDLI [NASD]
PDL BioPharma, Inc.
Index- P/E7.32 EPS (ttm)0.45 Insider Own1.00% Shs Outstand151.74M Perf Week3.12%
Market Cap502.26M Forward P/E8.07 EPS next Y0.41 Insider Trans1.68% Shs Float150.10M Perf Month18.21%
Income71.30M PEG0.52 EPS next Q0.13 Inst Own85.90% Short Float12.09% Perf Quarter34.55%
Sales309.40M P/S1.62 EPS this Y-81.00% Inst Trans-2.20% Short Ratio10.31 Perf Half Y61.46%
Book/sh5.26 P/B0.63 EPS next Y-32.79% ROA5.70% Target Price3.50 Perf Year2.48%
Cash/sh2.87 P/C1.15 EPS next 5Y14.00% ROE9.30% 52W Range1.93 - 3.77 Perf YTD56.13%
Dividend- P/FCF- EPS past 5Y-6.60% ROI8.30% 52W High-12.20% Beta0.55
Dividend %- Quick Ratio1.90 Sales past 5Y-7.60% Gross Margin96.40% 52W Low71.50% ATR0.10
Employees11 Current Ratio1.90 Sales Q/Q584.80% Oper. Margin51.70% RSI (14)75.56 Volatility2.40% 3.49%
OptionableYes Debt/Eq0.29 EPS Q/Q1357.10% Profit Margin23.00% Rel Volume0.84 Prev Close3.29
ShortableYes LT Debt/Eq0.14 EarningsAug 03 AMC Payout0.00% Avg Volume1.76M Price3.31
Recom2.50 SMA207.19% SMA5021.31% SMA20040.18% Volume1,521,786 Change0.61%
Dec-22-16Resumed Piper Jaffray Overweight
Feb-23-16Reiterated RBC Capital Mkts Sector Perform $5 → $4
Feb-02-16Reiterated RBC Capital Mkts Sector Perform $6 → $5
Nov-05-15Reiterated RBC Capital Mkts Sector Perform $7 → $6
Oct-16-15Reiterated RBC Capital Mkts Sector Perform $8 → $7
Jan-20-11Upgrade RBC Capital Mkts Sector Perform → Outperform $6 → $6
Sep-10-10Initiated RBC Capital Mkts Sector Perform $6
Mar-27-09Upgrade Lazard Capital Mkts Hold → Buy $8
Mar-03-09Reiterated Wedbush Morgan Buy $15 → $9
Mar-03-09Reiterated JMP Securities Mkt Outperform $16 → $9
Jan-05-09Upgrade JP Morgan Underweight → Neutral
Dec-10-08Reiterated Credit Suisse Neutral $11 → $12
Sep-11-08Downgrade JP Morgan Neutral → Underweight
Jun-13-08Downgrade Credit Suisse Outperform → Neutral
May-12-08Reiterated Lehman Brothers Equal-Weight $16 → $12
Apr-22-08Downgrade Wachovia Outperform → Mkt Perform
Apr-11-08Reiterated Credit Suisse Outperform $19 → $16
Mar-10-08Downgrade Susquehanna Financial Positive → Neutral
Mar-06-08Reiterated BMO Capital Markets Market Perform $18 → $14
Mar-05-08Downgrade Lehman Brothers Overweight → Equal-weight $21 → $13
Sep-20-17 02:10PM  ProQR's Genetic Disorder Candidate Gets Orphan Drug Status Zacks
09:45AM  Should Value Investors Consider PDL BioPharma, Inc. (PDLI) Stock? Zacks
Sep-19-17 10:35AM  Pluristem's Ischemia Candidate Gets Fast Track Designation Zacks
07:00AM  PDL BioPharma Updates Presentation Time for Cantor Fitzgerald Conference PR Newswire
Sep-13-17 11:25AM  3 Pharma/Biotech Sector Bargains for a Healthy Portfolio Zacks
Sep-11-17 04:02PM  PDL BioPharma Appoints Dominique Monnet as President PR Newswire
Sep-06-17 07:00AM  PDL BioPharma to Present at Two Upcoming Investor Conferences PR Newswire
Aug-28-17 08:44AM  Why PDL BioPharma (PDLI) Could Be Positioned for a Surge Zacks
Aug-25-17 09:21AM  Zacks.com featured highlights Summer Infant, Intra-Cellular Therapies, PDL BioPharma, Cogentix Medical and Intrepid Potash Zacks +5.26%
Aug-24-17 09:45AM  Top Ranked Momentum Stocks to Buy for August 24th Zacks
09:35AM  5 Bargain Breakout Stocks Offering Stunning Returns Zacks
Aug-23-17 10:48AM  Top Ranked Momentum Stocks to Buy for August 23rd Zacks
Aug-18-17 08:34AM  3 Reasons Why PDL BioPharma (PDLI) is a Great Momentum Stock Zacks
Aug-17-17 02:11PM  Edited Transcript of PDLI earnings conference call or presentation 3-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-16-17 10:41AM  Top Ranked Momentum Stocks to Buy for August 16th Zacks
Aug-14-17 05:08PM  ETFs with exposure to PDL BioPharma, Inc. : August 14, 2017 Capital Cube
Aug-07-17 04:32PM  PDL BioPharma (PDLI) Q2 Earnings Beat, Revenues Rise Y/Y Zacks +8.37%
Aug-04-17 12:51PM  Here's Why PDL BioPharma Inc. Is Soaring Today Motley Fool +10.14%
Aug-03-17 11:07PM  PDL BioPharma, Inc. Value Analysis (NASDAQ:PDLI) : August 4, 2017 Capital Cube
09:11PM  ETFs with exposure to PDL BioPharma, Inc. : August 4, 2017 Capital Cube
04:02PM  PDL BioPharma Announces Second Quarter 2017 Financial Results PR Newswire
12:00PM  Investor Network: PDL BioPharma, Inc. to Host Earnings Call ACCESSWIRE
Jul-31-17 09:56AM  PDL BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : PDLI-US : July 31, 2017 Capital Cube
07:00AM  PDL BioPharma to Announce Second Quarter 2017 Financial Results on August 3, 2017 PR Newswire
Jul-24-17 06:00PM  ETFs with exposure to PDL BioPharma, Inc. : July 24, 2017 Capital Cube
Jul-21-17 09:21AM  PDL BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : PDLI-US : July 21, 2017 Capital Cube
Jul-13-17 04:26PM  ETFs with exposure to PDL BioPharma, Inc. : July 13, 2017 Capital Cube
Jul-10-17 09:35AM  PDL BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : PDLI-US : July 10, 2017 Capital Cube
Jul-03-17 03:40PM  ETFs with exposure to PDL BioPharma, Inc. : July 3, 2017 Capital Cube
Jun-20-17 03:11PM  ETFs with exposure to PDL BioPharma, Inc. : June 20, 2017 Capital Cube
Jun-19-17 11:48AM  PDL BioPharma, Inc. :PDLI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017 Capital Cube
08:21AM  PDL BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : PDLI-US : June 19, 2017 Capital Cube
Jun-05-17 07:00AM  Noden Pharma Notified of ANDA Filing for Tekturna® PR Newswire
Jun-01-17 07:00AM  PDL BioPharma to Present at the Jefferies 2017 Healthcare Conference PR Newswire
May-11-17 07:00AM  LENSAR® And PDL BioPharma Complete Strategic Financial Restructuring Of LENSAR PR Newswire -5.42%
May-06-17 08:26PM  Edited Transcript of PDLI earnings conference call or presentation 3-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-05-17 04:31PM  LENSAR® Receives FDA Clearances for Laser Cataract Platform Integration With OCULUS Pentacam® Tomographers Business Wire
May-03-17 05:32PM  PDL BioPharma posts 1Q profit Associated Press
04:02PM  PDL BioPharma Announces First Quarter 2017 Financial Results PR Newswire
08:45AM  Investor Network: PDL BioPharma, Inc. to Host Earnings Call Accesswire
Apr-26-17 04:27PM  PDL BioPharma, Inc. Value Analysis (NASDAQ:PDLI) : April 26, 2017 Capital Cube
07:00AM  PDL BioPharma to Announce First Quarter 2017 Financial Results on May 3, 2017 PR Newswire
Apr-25-17 08:58AM  PDL BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : PDLI-US : April 25, 2017 Capital Cube
Apr-24-17 02:39PM  ETFs with exposure to PDL BioPharma, Inc. : April 24, 2017 Capital Cube +6.93%
11:03AM  Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers TheStreet.com
07:11AM  PDL BioPharma to be paid $19.5 million by Merck to settle Keytruda patent suit MarketWatch
07:00AM  PDL BioPharma Announces Settlement of Keytruda Patent Infringement Lawsuit with Merck PR Newswire
Apr-06-17 04:02PM  PDL BioPharma to Hold Annual Meeting of Stockholders on June 9, 2017 PR Newswire
Apr-03-17 08:17AM  PDL BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : PDLI-US : April 3, 2017 Capital Cube
02:18AM  PDL BioPharma (PDLI) Up 5.9% Since Earnings Report: Can It Continue? Zacks
Mar-31-17 09:30AM  Today's Research Reports on Stocks to Watch: Celldex Therapeutics and PDL BioPharma Accesswire +5.09%
Mar-27-17 04:03PM  ETFs with exposure to PDL BioPharma, Inc. : March 27, 2017 Capital Cube
Mar-21-17 06:02AM  PDL BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-17-17 08:37AM  PDL BioPharma, Inc. :PDLI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Capital Cube
Mar-14-17 07:00AM  PDL BioPharma to Present at the Oppenheimer 27th Annual Healthcare Conference PR Newswire
06:03AM  PDL BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-10-17 02:32PM  PDL BioPharma, Inc. :PDLI-US: Earnings Analysis: 2016 By the Numbers : March 10, 2017 Capital Cube
07:12AM  PDL BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Mar-08-17 06:02AM  PDL BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-07-17 01:04PM  PDL BIOPHARMA, INC. Financials
Mar-03-17 04:24PM  Why Tenet Healthcare, Scientific Games, and PDL BioPharma Jumped Today Motley Fool +6.13%
Mar-02-17 07:00AM  PDL BioPharma to Present at Two Upcoming Investor Conferences PR Newswire
Mar-01-17 10:07PM  Edited Transcript of PDLI earnings conference call or presentation 1-Mar-17 9:30pm GMT
04:46PM  PDL BioPharma reports 4Q loss
04:11PM  PDL BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fina
04:02PM  PDL BioPharma Announces Fourth Quarter and Year End 2016 Financial Results PR Newswire
07:07AM  Q4 2016 PDL BioPharma Inc Earnings Release - After Market Close
07:00AM  PDL BioPharma Announces $30 Million Share Repurchase Program PR Newswire
Feb-27-17 09:50AM  Better Buy: PDL BioPharma, Inc. vs. Johnson & Johnson at Motley Fool
Feb-22-17 07:00AM  PDL BioPharma to Announce Fourth Quarter / Year-End 2016 Financial Results on March 1, 2017 PR Newswire
Feb-21-17 05:51PM  8 High-Yield Stocks With Falling Prices
06:09AM  PDL BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Feb-17-17 07:00AM  PDL BioPharma to Present at the 2017 RBC Capital Markets Global Healthcare Conference PR Newswire
Feb-15-17 09:30AM  9 Top Pharmaceutical Stocks to Buy for the Dividends at Kiplinger
Jan-31-17 08:00AM  PDL BioPharma Inc. Review of 3Q 2016 Results and Forward Outlook Accesswire
Jan-26-17 09:05AM  LENSAR® Launches Streamline III to Assist Cataract Surgeons in Managing and Improving Astigmatism Treatment for Optimal Visual Outcomes Business Wire
Jan-20-17 01:42PM  ETFs with exposure to PDL BioPharma, Inc. : January 20, 2017
Jan-19-17 09:45AM  Can PDL BioPharma Be a Top Choice for Value Investors?
Jan-09-17 06:20AM  PDL BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Dec-20-16 05:15PM  PDL BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events
Dec-19-16 04:56PM  [$$] Medical-Device Company Enters Chapter 11 at The Wall Street Journal
12:48PM  Big Changes to BioShares Biotech ETFs: Who's In, Who's Out?
11:59AM  ETFs with exposure to PDL BioPharma, Inc. : December 19, 2016
09:54AM  LENSAR® Strategic Restructure in Partnership with PDL BioPharma, Inc. Business Wire
Dec-16-16 04:12PM  PDL BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Dec-12-16 09:44AM  Is Vera Bradley, Inc. (VRA) Worthy of Your Portfolio? at Insider Monkey -8.04%
Dec-08-16 07:39AM  Pace Holdings Corp (PACE): Hedge Fund Sentiment Unchanged at Insider Monkey +5.77%
Dec-05-16 12:27PM  ETFs with exposure to PDL BioPharma, Inc. : December 5, 2016
Dec-02-16 10:24AM  Here's Why PDL BioPharma Inc. Imploded and Fell 32% in November at Motley Fool
03:24AM  Is PDL BioPharma Inc (PDLI) Going to Burn These Hedge Funds? at Insider Monkey
Dec-01-16 10:47AM  3 Drug Stocks Investors Shouldn't Touch With a 10-Foot Pole in 2017 at Motley Fool
Nov-29-16 04:04PM  Fitbit, Vodafone Sink into Tuesdays 52-Week Low Club at 24/7 Wall St.
07:16AM  PDL BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Nov-28-16 04:04PM  PDL BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Ob -5.51%
04:04PM  Vodafone, Towerstream Slide into Mondays 52-Week Low Club at 24/7 Wall St.
Nov-23-16 01:20PM  ETFs with exposure to PDL BioPharma, Inc. : November 23, 2016 -14.52%
12:57PM  Why PDL BioPharma Inc. Is Down 14.8% Today at Motley Fool
Nov-22-16 05:15PM  PDL BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secur
02:44PM  PDL BioPharma Issues $150.0 Million of 2.75% Convertible Senior Notes Due 2021 PR Newswire
10:10AM  PDL BioPharma, Inc. :PDLI-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016
PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates through two segments, Income Generating Assets and Product Sales. The Income Generating Assets segment consists of royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri; and notes and other long-term receivables, royalty rights, hybrid notes/royalties receivable, and equity investments in healthcare companies. The Product Sales segment, through its equity and loan investments, manufactures, markets, and sells prescription pharmaceutical products under the Tekturna and Tekturna HCT names in the United States; and Rasilez and Rasilez HCT names internationally for the treatment of hypertension. This segment sells its products primarily to wholesalers. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GARCIA PETER SVice President, CFOMar 24Buy1.9825,00049,401472,842Mar 27 05:51 PM